Lawrence Lee co-wrote this blog post with Nicolle Hamilton.
The oncology pipeline is rich with potential combination regimens across both liquid and solid tumor types. Several manufacturers are developing or marketing PD-1/PD-L1 checkpoint inhibitors as a “backbone” for their combination regimen portfolio. Although there are only a few currently marketed regimens with multiple targeted agents (such as Opdivo-Yervoy in ovarian cancer, Tafinlar-Mekinist in metastatic melanoma, and several combos in multiple myeloma), combination approaches may become the standard of care for many tumor types. Indeed, these novel-novel approaches can yield compelling clinical outcomes. For example, Opdivo-Yervoy reduced progression risk by 58% vs. Yervoy alone in melanoma.
In a few short years, the treatment landscape for patients with hematologic malignancies has been transformed into a world of choices. The upcoming American Society of Hematology (ASH) Annual Meeting, which will be held Dec. 3-6 in San Diego, will bring more data to the forefront—with much more to come in the next five years—that builds on the recent trend of attacking cancer via multiple pathways through combination therapy regimens.
So far, the event abstracts already show a wide array of combination therapies in most tumor types: acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia, among many others. As the data for combination regimens continues to build, we expect many more approvals in the next few years, and with this ever-lengthening list of combination therapies comes greater hope for patients.